Lineage Cell Therapeutics
LCTX
LCTX
74 hedge funds and large institutions have $99.9M invested in Lineage Cell Therapeutics in 2016 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 16 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.9% less ownership
Funds ownership: 43.69% → 42.79% (-0.9%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $241K
Holders
74
Holding in Top 10
1
Calls
–
Puts
$241K
Top Buyers
| 1 | +$7.13M | |
| 2 | +$1.07M | |
| 3 | +$545K | |
| 4 |
State Street
Boston,
Massachusetts
|
+$258K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$193K |
Top Sellers
| 1 | -$246K | |
| 2 | -$229K | |
| 3 | -$103K | |
| 4 |
D.E. Shaw & Co
New York
|
-$96K |
| 5 |
FM
Family Management
New York
|
-$49.6K |